Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{b480eb971f6248d6b4f36f9e11e49fff,
title = "Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial",
abstract = "The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).",
keywords = "Absorptiometry, Photon, Adult, Antiretroviral Therapy, Highly Active, Benzoxazines, Bone Density, Female, HIV Infections, HIV-1, Humans, Lamivudine, Male, Pyrimidinones, Ritonavir, Zidovudine",
author = "Hansen, {Ann-Brit Eg} and N Obel and H Nielsen and C Pedersen and J Gerstoft",
note = "{\textcopyright} 2010 British HIV Association.",
year = "2011",
month = mar,
day = "1",
doi = "10.1111/j.1468-1293.2010.00864.x",
language = "English",
volume = "12",
pages = "157--65",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

AU - Hansen, Ann-Brit Eg

AU - Obel, N

AU - Nielsen, H

AU - Pedersen, C

AU - Gerstoft, J

N1 - © 2010 British HIV Association.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).

AB - The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART).

KW - Absorptiometry, Photon

KW - Adult

KW - Antiretroviral Therapy, Highly Active

KW - Benzoxazines

KW - Bone Density

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Lamivudine

KW - Male

KW - Pyrimidinones

KW - Ritonavir

KW - Zidovudine

U2 - 10.1111/j.1468-1293.2010.00864.x

DO - 10.1111/j.1468-1293.2010.00864.x

M3 - Journal article

C2 - 20722752

VL - 12

SP - 157

EP - 165

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 3

ER -

ID: 32773871